New combo therapy targets Hard-to-Treat cancers
NCT ID NCT07612137
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tests a new drug combination (IBI3005) in about 282 adults with advanced solid tumors that have spread or cannot be removed by surgery. The main goals are to check safety and see if the treatment shrinks tumors. Participants will be closely monitored for side effects and how their cancer responds.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for NON-SMALL CELL LUNG CANCER are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
SunYat-sen University Cancer Center
Guangzhou, Guangdong, 510060, China
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a new drug shield nerves from Chemotherapy's side effects?
- Can a new immunotherapy combo outsmart advanced lung cancer?
- Can a Tumor's DNA guide better cancer care for kids?
- Double attack on mutant KRAS: can two targeted drugs outsmart resistant cancers?
- Seeing the fight: new imaging tracer may reveal how immune cells attack lung cancer
- Could a bronchial wash detect lung cancer mutations faster?